Development of biodegradable controlled release scleral systems of triamcinolone acetonide.

PURPOSE: To develop scleral controlled-release-systems of triamcinolone acetonide (TA) based on biodegradable poly(lactide) (PLA). MATERIALS AND METHODS: (1) PLA microspheres containing TA were prepared by a single or double emulsification-solvent evaporation method. Morphology, size, effect of drug input and method of microsphere preparation on drug loading, and in vitro TA release of the microspheres were investigated. (2) Mini-tablets consisting of blank PLA-microspheres and TA (weight ratios of 1:1, 2:1, and 4:1, respectively) were developed and their release profile in vitro was evaluated. (3) The in vitro transscleral diffusion profile was evaluated by placing a PLA-TA (1:1) tablet in a donor chamber and measuring the TA concentration in a receptor chamber. Donor and receptor chambers were separated by rabbit sclera. (4) Two cadaver rabbit eyes received a 1:1 PLA-TA tablet episclerally, which was covered by a scleral patch. TA aqueous humor and vitreous concentrations were measured 5, 10, and 20 days post implantation. RESULTS: (1) Microsphere average size was 2 µm. The double emulsification method and increasing drug input led to an increase in drug loading and encapsulation. Sustained release of TA over several days from the microspheres in vitro was observed, with the rate of release being affected by their TA content. (2) TA exhibited sustained release profile from the PLA-TA tablets, with the rate of release being affected by the PLA:TA ratio. (3) TA could slowly cross the sclera tissue in vitro, with approximately 21% of the drug loaded in the donor compartment being diffused through the sclera in 45 days. (4) Following scleral administration of the PLA-TA mini-tablets, TA accumulated in the vitreous and aqueous humor of cadaver eyes. CONCLUSIONS: The PLA-TA microspheres and mini-tablets appear promising for the controlled transscleral delivery of TA and justify further investigation.

Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers.

Novel amphiphilic triblock copolymers of poly(propylene succinate) (PPSu) and poly(ethylene glycol) (PEG) with different hydrophobic/hydrophilic ratios were synthesized using a facile one-pot procedure. The molecular weight of the copolymers was adjusted by varying the molecular weight of PPSu while keeping that of PEG constant. The copolymers exhibited glass transition temperatures between -36.0 and -38°C and single melting points around 44°C. WAXD data indicated that both blocks of the copolymers could crystallize. The mPEG-PPSu copolymers exhibited low in vitro toxicity against HUVEC cells. The synthesized copolymers were used to prepare core-shell nanoparticles with hydrophobic PPSu and hydrophilic PEG forming the core and shell, respectively. The drug loading efficiency and drug release properties of the mPEG-PPSu nanoparticles were investigated using two model drugs: the hydrophilic Ropinirole and the hydrophobic Tibolone. The mean size of the drug-loaded mPEG-PPSu nanoparticles ranged between 150 and 300nm and increased with the molecular weight of the PPSu block. The drug loading efficiency of the nanoparticles was found to be dependent upon drug hydrophilicity and was much higher for the hydrophobic Tibolone. Drug release characteristics also depended on drug hydrophilicity: the hydrophilic Ropinirole was released at a much higher rate than the hydrophobic Tibolone. Contrary to Ropinirole, the profiles of Tibolone exhibited an early phase of burst release followed by a phase of slow release. By varying the composition (mPEG/PPSu ratio) of mPEG-PPSU copolymers, nanoparticles of different sizes and drug loading capacities can be synthesized exhibiting different drug release characteristics. Based on the results obtained, the proposed mPEG-PPSu copolymers can be useful in various controlled drug delivery applications, especially those involving relatively hydrophobic drugs.

Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin.

The effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin was investigated. A modified double emulsion method was applied for the preparation of PLGAmPEG nanoparticles of cisplatin, based on the partial or complete replacement of the water of the inner aqueous phase of the emulsion by dimethyl formamide(dmf) or the addition of cisplatin in the form of a complex with poly(glutamic acid). These modifications resulted in significant improvement of cisplatin loading in the PLGA-mPEG nanoparticles. Increased cisplatin loading and encapsulation efficiency were obtained when a relatively low dmf/water ratio, low dmf volume (when pure dmf formed the inner polar phase), or a high drug/polymer ratio were applied. A reduction of average size of nanoparticles was observed with decreasing the amount of PLGA-mPEG added in the formulation or increasing sonication time. The only factor that had a significant effect on size distribution was the sonication time, with the size P.I. being decreased with increasing sonication time. Prolonged sonication, however, decreased cisplatin loading and encapsulation efficiency. From the four lyoprotectant sugars tested (glucose, lactose, mannitol, and trehalose), only mannitol could prevent nanoparticle aggregation upon lyophilization. When appropriate amounts of an effective lyoprotectant were added in nanoparticles before lyophilization, drug loading of the nanoparticles was not affected by nanoparticle lyophilization.